RxDoctor Payments Data

Aaron Salyapongse, MD

Adult Reconstructive Orthopaedic Surgery · Dublin, CANPI 1598711681

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (48.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Depuy Synthes Products, Inc. at 52.2% of the total. Reporting peaked in 2022 at $258,776 and has fallen 91.9% since, to $20,954 in 2025.

$458,027in general payments, 2019–2025

Across 221 payments — averaging $2072.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Depuy Synthes Products, Inc.$239K
  • Microport Orthopedics Inc$97K
  • Kyocera Medical Technologies, Inc.$73K
  • Medical Device Business Services, Inc.$48K
  • Johnson & Johnson$494
  • Zimmer Biomet$270
  • plus $323 from 7 others

What the payments were for

  • Royalty or licence$220,00048%
  • Consulting fees$178,64639%
  • Speaking & faculty fees$28,5646%
  • Travel & lodging$23,0375%
  • Food & beverage$7,7812%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$458,027 in reported general payments places this provider in the 85th percentile of 136 adult reconstructive orthopaedic surgery providers in California.

See all adult reconstructive orthopaedic surgery providers in California

Medicare billing

Part B allowed, 2024
$429,379
Medicare patients
602
Services billed
1,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib16$485
Oxycodone Hcl12$78
Amoxicillin11$15

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Dublin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →